Citations

Clear

1011 citation(s) found for "Barry, WT".

Genetic Determinants of Emphysema Distribution in the National Emphysema Treatment Trial
DeMeo, Dawn L. , Hoffman, Eric A. , Litonjua, Augusto A. , Lazarus, Ross , Sparrow, David , Benditt, Joshua O., Scanlon, Paul D., Sciurba, Frank C. , Utz, James P., Reilly, John J. , Silverman, Edwin K. , Hersh, Craig P. , Criner, Gerard J. , Make, Barry J. , Martínez, Fernando J. , Hoffman, Eric A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 15, 2007 | Volume: 176 | Issue: 1 | Pages: 42-48

10.1164/rccm.200612-1797oc | PMID 17363767 Get It

Abstract Rationale Computed tomography (CT) scanning of the lung may reduce phenotypic heterogeneity in defining subjects with chronic obstructive pulmonary disease (COPD), and allow identification of genetic determinants of emphysema severity and distribution. Objectives We sought to identify genes associated with CT scan distribution of emphysema in individuals without α1-antitrypsin deficiency but with severe COPD. Methods We evaluated baseline CT densitometry phenotypes in 282 individuals with emphysema enrolled in the Genetics Ancillary Study of the National Emphysema Treatment Trial, and used regression models to identify genetic variants associated with emphysema distribution. Measurements and Main Results Emphysema distribution was assessed by two methods—assessment by radiologists and by computerized density mask quantitation, using a threshold of −950 Hounsfield units. A total of 77 polymorphisms in 20 candidate genes were analyzed for association with distribution of emphysema. GSTP1, EPHX1, and MMP1 polymorphisms were associated with the densitometric, apical-predominant distribution of emphysema (p value range = 0.001–0.050). When an apical-predominant phenotype was defined by the radiologist scoring method, GSTP1 and EPHX1 single-nucleotide polymorphisms were found to be significantly associated. In a case–control analysis of COPD susceptibility limited to cases with densitometric upper-lobe–predominant cases, the EPHX1 His139Arg single-nucleotide polymorphism was associated with COPD (p = 0.005). Conclusions Apical and basal emphysematous destruction appears to be influenced by different genes. Polymorphisms in the xenobiotic enzymes, GSTP1 and EPHX1, are associated with apical-predominant emphysema. Altered detoxification of cigarette smoke metabolites may contribute to emphysema distribution, and these findings may lead to further insight into genetic determinants of emphysema.
Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Andrei, Adin‐Cristian , King, Talmadge E. , Raghu, Ganesh , Colby, Thomas V. , Wells, Athol U. , Bassily, Nadir, Brown, Kevin K. , Bois, Roland du, Flint, Andrew , Gay, Steven E., Gross, Barry H., Kazerooni, Ella A. , Knapp, Robert H., Louvar, Edmund, Lynch, David A. , Quick, John S., Vyskocil, J , Wadenstorer, Frazer A., Wilt, Jeffrey, Toews, Galen B., Murray, Susan , Nicholson, Andrew G. , Thannickal, Victor J. , Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 25, 2007 | Volume: 175 | Issue: 10 | Pages: 1054-1060

10.1164/rccm.200606-833oc | PMID 17255566 Get It

Abstract Rationale Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult. Objectives Evaluate diagnostic agreement between academic and community-based physicians for patients with DPLDs, and determine if an interactive approach between clinicians, radiologists, and pathologists improved diagnostic agreement in community and academic centers. Methods Retrospective review of 39 patients with DPLD. A total of 19 participants reviewed cases at 2 community locations and 1 academic location. Information from the history, physical examination, pulmonary function testing, high-resolution computed tomography, and surgical lung biopsy was collected. Data were presented in the same sequential fashion to three groups of physicians on separate days. Measurements and Main Results Each observer's diagnosis was coded into one of eight categories. A κ statistic allowing for multiple raters was used to assess agreement in diagnosis. Interactions between clinicians, radiologists, and pathologists improved interobserver agreement at both community and academic sites; however, final agreement was better within academic centers (κ = 0.55–0.71) than within community centers (κ = 0.32–0.44). Clinically significant disagreement was present between academic and community-based physicians (κ = 0.11–0.56). Community physicians were more likely to assign a final diagnosis of idiopathic pulmonary fibrosis compared with academic physicians. Conclusions Significant disagreement exists in the diagnosis of DPLD between physicians based in communities compared with those in academic centers. Wherever possible, patients should be referred to centers with expertise in diffuse parenchymal lung disorders to help clarify the diagnosis and provide suggestions regarding treatment options.
Cryoelectron Microscopy of Protein IX-Modified Adenoviruses Suggests a New Position for the C Terminus of Protein IX
Marsh, Michael P., Campos, Samuel K. , Baker, Matthew L. , Chen, Christopher Y. , Chiu, Wah , Barry, Michael A. , Barry, Michael A , Campos, Samuel K

Mayo Clinic

Journal of Virology | November 13, 2006 | Volume: 80 | Issue: 23 | Pages: 11881-11886

10.1128/jvi.01471-06 | PMID 16987967 Get It

ABSTRACT Recombinant human adenovirus is a useful gene delivery vector for clinical gene therapy. Minor capsid protein IX of adenovirus has been of recent interest since multiple studies have shown that modifications can be made to its C terminus to alter viral tropism or add molecular tags and/or reporter proteins. We examined the structure of an engineered adenovirus displaying the enhanced green fluorescent protein (EGFP) fused to the C terminus of protein IX. Cryoelectron microscopy and reconstruction localized the C-terminal EGFP fusion between the H2 hexon and the H4 hexon, positioned between adjacent facets, directly above the density previously assigned as protein IIIa. The original assignment of IIIa was based largely on indirect evidence, and the data presented herein support the reassignment of the IIIa density as protein IX.
Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction
Melenovský, Vojtěch , Kessler, Kristy, Pacák, Karel , Becker, Lewis C. , Borlaug, Barry A. , Russell, Stuart D. , Kass, David A. , Melenovský, Vojtěch

Mayo Clinic

Circulation | November 7, 2006 | Volume: 114 | Issue: 20 | Pages: 2138-2147

10.1161/circulationaha.106.632745 | PMID 17088459 Get It

Background— Nearly half of patients with heart failure have a preserved ejection fraction (HFpEF). Symptoms of exercise intolerance and dyspnea are most often attributed to diastolic dysfunction; however, impaired systolic and/or arterial vasodilator reserve under stress could also play an important role. Methods and Results— Patients with HFpEF (n=17) and control subjects without heart failure (n=19) generally matched for age, gender, hypertension, diabetes mellitus, obesity, and the presence of left ventricular hypertrophy underwent maximal-effort upright cycle ergometry with radionuclide ventriculography to determine rest and exercise cardiovascular function. Resting cardiovascular function was similar between the 2 groups. Both had limited exercise capacity, but this was more profoundly reduced in HFpEF patients (exercise duration 180±71 versus 455±184 seconds; peak oxygen consumption 9.0±3.4 versus 14.4±3.4 mL · kg −1 · min −1 ; both P <0.001). At matched low-level workload, HFpEF subjects displayed ≈40% less of an increase in heart rate and cardiac output and less systemic vasodilation (all P <0.05) despite a similar rise in end-diastolic volume, stroke volume, and contractility. Heart rate recovery after exercise was also significantly delayed in HFpEF patients. Exercise capacity correlated with the change in cardiac output, heart rate, and vascular resistance but not end-diastolic volume or stroke volume. Lung blood volume and plasma norepinephrine levels rose similarly with exercise in both groups. Conclusions— HFpEF patients have reduced chronotropic, vasodilator, and cardiac output reserve during exercise compared with matched subjects with hypertensive cardiac hypertrophy. These limitations cannot be ascribed to diastolic abnormalities per se and may provide novel therapeutic targets for interventions to improve exercise capacity in this disorder.
An X-band hybrid MIC feedforward amplifier for low residual noise operation
Соколов, В. А. , Kruchowski, James, Vickberg, M., Buhrow, Benjamin , Schuster, S.E., Bublitz, J., Gilbert, Barry K., Daniel, Erik S.

Mayo Clinic

IEEE MTT-S International Microwave Symposium Digest, 2005. | October 11, 2006 | Volume: No volume available | Issue: No issue available | Pages: 2039-2042

10.1109/mwsym.2005.1517146 Get It

National Center for Biomedical Ontology: Advancing Biomedicine through Structured Organization of Scientific Knowledge
Lewis, Suzanna , Mungall, Chris , Misra, Sima, Westerfield, Monte , Ashburner, Michael , Solbrig, Harold R. , Storey, Margaret‐Anne , Smith, Barry , Day-Richter, John, Noy, Natalya F., Musen, Mark A. , Rubin, Daniel L. , Sim, Ida , Chute, Christopher G. , Mungall, Christopher J

Mayo Clinic

OMICS: A Journal of Integrative Biology | August 10, 2006 | Volume: 10 | Issue: 2 | Pages: 185-198

10.1089/omi.2006.10.185 | PMID 16901225 Get It

The National Center for Biomedical Ontology is a consortium that comprises leading informaticians, biologists, clinicians, and ontologists, funded by the National Institutes of Health (NIH) Roadmap, to develop innovative technology and methods that allow scientists to record, manage, and disseminate biomedical information and knowledge in machine-processable form. The goals of the Center are (1) to help unify the divergent and isolated efforts in ontology development by promoting high quality open-source, standards-based tools to create, manage, and use ontologies, (2) to create new software tools so that scientists can use ontologies to annotate and analyze biomedical data, (3) to provide a national resource for the ongoing evaluation, integration, and evolution of biomedical ontologies and associated tools and theories in the context of driving biomedical projects (DBPs), and (4) to disseminate the tools and resources of the Center and to identify, evaluate, and communicate best practices of ontology development to the biomedical community. Through the research activities within the Center, collaborations with the DBPs, and interactions with the biomedical community, our goal is to help scientists to work more effectively in the e-science paradigm, enhancing experiment design, experiment execution, data analysis, information synthesis, hypothesis generation and testing, and understand human disease. This paper is part of the special issue of OMICS on data standards.
Idiopathic Pulmonary Fibrosis
Flaherty, Kevin R. , Andrei, Adin‐Cristian , Murray, Susan , Fraley, Chris, Colby, Thomas V. , Lama, Vibha N. , Kazerooni, Ella A. , Gross, Barry H., Toews, Galen B., Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 6, 2006 | Volume: 174 | Issue: 7 | Pages: 803-809

10.1164/rccm.200604-488oc | PMID 16825656 Get It

Abstract Rationale and Hypothesis Idiopathic pulmonary fibrosis is a fatal disease with a variable rate of progression. We hypothesized that changes in distance walked and quantity of desaturation during a six-minute-walk test (6MWT) would add prognostic information to changes in FVC or diffusing capacity for carbon monoxide. Methods One hundred ninety-seven patients with idiopathic pulmonary fibrosis were evaluated. Desaturation during the 6MWT was associated with increased mortality even if a threshold of 88% was not reached. Baseline walk distance predicted subsequent walk distance but was not a reliable predictor of subsequent mortality in multivariate survival models. The predictive ability of serial changes in physiology varied when patients were stratified by the presence/absence of desaturation ⩽ 88% during a baseline 6MWT. For patients with a baseline saturation ⩽ 88% during a 6MWT, the strongest observed predictor of mortality was serial change in diffusing capacity for carbon monoxide. For patients with saturation &gt; 88% during their baseline walk test, serial decreases in FVC and increases in desaturation area significantly predicted subsequent mortality, whereas decreases in walk distance and in diffusing capacity for carbon monoxide displayed less consistent statistical evidence of increasing mortality in our patients. Conclusion These data highlight the importance of stratifying patients by degree of desaturation during a 6MWT before attributing prognostic value to serial changes in other physiologic variables.
Genetic Association Analysis of Functional Impairment in Chronic Obstructive Pulmonary Disease
DeMeo, Dawn L. , Lazarus, Ross , Celedón, Juan C. , Raby, Benjamin A. , Benditt, Joshua O., Scanlon, Paul D., Sciurba, Frank C. , Utz, James P., Reilly, John J. , Silverman, Edwin K. , Hersh, Craig P. , Criner, Gerard J. , Make, Barry J. , Martínez, Fernando J. , Celedón, Juan C

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 2, 2006 | Volume: 173 | Issue: 9 | Pages: 977-984

10.1164/rccm.200509-1452oc | PMID 16456143 Get It

Abstract Rationale Patients with severe chronic obstructive pulmonary disease (COPD) may have varying levels of disability despite similar levels of lung function. This variation may reflect different COPD subtypes, which may have different genetic predispositions. Objectives To identify genetic associations for COPD-related phenotypes, including measures of exercise capacity, pulmonary function, and respiratory symptoms. Methods In 304 subjects from the National Emphysema Treatment Trial, we genotyped 80 markers in 22 positional and/or biologically plausible candidate genes. Regression models were used to test for association, using a test–replication approach to guard against false-positive results. For significant associations, effect estimates were recalculated using the entire cohort. Positive associations with dyspnea were confirmed in families from the Boston Early-Onset COPD Study. Results The test–replication approach identified four genes—microsomal epoxide hydrolase (EPHX1), latent transforming growth factor-β binding protein-4 (LTBP4), surfactant protein B (SFTPB), and transforming growth factor-β1 (TGFB1)—that were associated with COPD-related phenotypes. In all subjects, single-nucleotide polymorphisms (SNPs) in EPHX1 (p ⩽ 0.03) and in LTBP4 (p ⩽ 0.03) were associated with maximal output on cardiopulmonary exercise testing. Markers in LTBP4 (p ⩽ 0.05) and SFTPB (p = 0.005) were associated with 6-min walk test distance. SNPs in EPHX1 were associated with carbon monoxide diffusing capacity (p ⩽ 0.04). Three SNPs in TGFB1 were associated with dyspnea (p ⩽ 0.002), one of which replicated in the family study (p = 0.02). Conclusions Polymorphisms in several genes seem to be associated with COPD-related traits other than FEV1. These associations may identify genes in pathways important for COPD pathogenesis.
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Konecny, Gottfried E. , Pegram, Mark D. , Venkatesan, Natarajan , Yang, Guorong , Rahmeh, Martina, Rusnak, David W., Spehar, Glenn, Mullin, Robert J., Keith, Barry R., Gilmer, Tona M. , Berger, Mark S., Podratz, Karl C. , Slamon, Dennis J. , Finn, Richard S. , Untch, Michael

Mayo Clinic

Cancer Research | February 1, 2006 | Volume: 66 | Issue: 3 | Pages: 1630-1639

10.1158/0008-5472.can-05-1182 | PMID 16452222 Get It

Abstract Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-positive cell lines. We further characterize its activity in combination with trastuzumab and analyze whether EGFR and HER-2 expression or changes induced in the activation of EGFR, HER-2, Raf, AKT, or extracellular signal-regulated kinase (ERK) are markers of drug activity. We report that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC50s (range, 0.010-18.6 μmol/L). Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation. Long-term in vivo lapatinib studies were conducted with human breast cancer xenografts in athymic mice. Treatment over 77 days resulted in a sustained and significant reduction in xenograft volume compared with untreated controls. For the combination of lapatinib plus trastuzumab, synergistic drug interactions were observed in four different HER-2-overexpressing cell lines. Moreover, lapatinib retained significant in vitro activity against cell lines selected for long-term outgrowth (&gt;9 months) in trastuzumab-containing (100 μg/mL) culture medium. These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab. (Cancer Res 2006; 66(3): 1630-9)
Prostate Brachytherapy Seed Migration To A Coronary Artery Found During Angiography
Bresnahan, John F., Stafford, Scott L., Karon, Barry L., King, Bernard F., Wilson, Torrence M., Davis, Brian J.

Mayo Clinic

Journal of Urology | January 18, 2006 | Volume: 168 | Issue: 3 | Pages: 1103-1103

10.1016/s0022-5347(05)64589-2 | PMID 12187237 Get It